These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 18550179)

  • 1. The use of chemokine antagonists in EAE models.
    Proudfoot AE; de Souza AL; Muzio V
    J Neuroimmunol; 2008 Jul; 198(1-2):27-30. PubMed ID: 18550179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kinin B2 receptor regulates chemokines CCL2 and CCL5 expression and modulates leukocyte recruitment and pathology in experimental autoimmune encephalomyelitis (EAE) in mice.
    Dos Santos AC; Roffê E; Arantes RM; Juliano L; Pesquero JL; Pesquero JB; Bader M; Teixeira MM; Carvalho-Tavares J
    J Neuroinflammation; 2008 Nov; 5():49. PubMed ID: 18986535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting monocyte recruitment in CNS autoimmune disease.
    Izikson L; Klein RS; Luster AD; Weiner HL
    Clin Immunol; 2002 May; 103(2):125-31. PubMed ID: 12027417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CCL2 and CCL5 mediate leukocyte adhesion in experimental autoimmune encephalomyelitis--an intravital microscopy study.
    dos Santos AC; Barsante MM; Arantes RM; Bernard CC; Teixeira MM; Carvalho-Tavares J
    J Neuroimmunol; 2005 May; 162(1-2):122-9. PubMed ID: 15833367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential effects of decoy chemokine (7ND) gene therapy on acute, biphasic and chronic autoimmune encephalomyelitis: implication for pathomechanisms of lesion formation.
    Park IK; Hiraki K; Kohyama K; Matsumoto Y
    J Neuroimmunol; 2008 Feb; 194(1-2):34-43. PubMed ID: 18155779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The murine gammaherpesvirus-68 chemokine-binding protein M3 inhibits experimental autoimmune encephalomyelitis.
    Millward JM; Holst PJ; Høgh-Petersen M; Thomsen AR; Christensen JP; Owens T
    J Neuroimmunol; 2010 Jul; 224(1-2):45-50. PubMed ID: 20537410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The expression and function of chemokines involved in CNS inflammation.
    Ubogu EE; Cossoy MB; Ransohoff RM
    Trends Pharmacol Sci; 2006 Jan; 27(1):48-55. PubMed ID: 16310865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The chemokine system in neuroinflammation: an update.
    Ransohoff RM
    J Infect Dis; 2002 Dec; 186 Suppl 2():S152-6. PubMed ID: 12424691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New insights into adaptive immunity in chronic neuroinflammation.
    Siffrin V; Brandt AU; Herz J; Zipp F
    Adv Immunol; 2007; 96():1-40. PubMed ID: 17981203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of chemokine receptors CCR7 and CCR8 in the CNS during ChREAE.
    Bielecki B; Mazurek A; Wolinski P; Glabinski A
    Scand J Immunol; 2007 Oct; 66(4):383-92. PubMed ID: 17850582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the chemokine system for multiple sclerosis treatment.
    Glabinsk AR; Ransohoff RM
    Curr Opin Investig Drugs; 2001 Dec; 2(12):1712-9. PubMed ID: 11892933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemokines and chemokine receptors in multiple sclerosis. Potential targets for new therapies.
    Szczuciński A; Losy J
    Acta Neurol Scand; 2007 Mar; 115(3):137-46. PubMed ID: 17295707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemokines, mononuclear cells and the nervous system: heaven (or hell) is in the details.
    Rebenko-Moll NM; Liu L; Cardona A; Ransohoff RM
    Curr Opin Immunol; 2006 Dec; 18(6):683-9. PubMed ID: 17010588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemokines and chemokine receptors in autoimmune encephalomyelitis as a model for central nervous system inflammatory disease regulation.
    Dogan RN; Karpus WJ
    Front Biosci; 2004 May; 9():1500-5. PubMed ID: 14977561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surgical excision of CNS-draining lymph nodes reduces relapse severity in chronic-relapsing experimental autoimmune encephalomyelitis.
    van Zwam M; Huizinga R; Heijmans N; van Meurs M; Wierenga-Wolf AF; Melief MJ; Hintzen RQ; 't Hart BA; Amor S; Boven LA; Laman JD
    J Pathol; 2009 Mar; 217(4):543-51. PubMed ID: 19023878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Using intravital microscopy to study the role of chemokines during infection and inflammation in the central nervous system.
    Teixeira MM; Vilela MC; Soriani FM; Rodrigues DH; Teixeira AL
    J Neuroimmunol; 2010 Jul; 224(1-2):62-5. PubMed ID: 20605228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of CCR6 function reduces the severity of experimental autoimmune encephalomyelitis via effects on the priming phase of the immune response.
    Liston A; Kohler RE; Townley S; Haylock-Jacobs S; Comerford I; Caon AC; Webster J; Harrison JM; Swann J; Clark-Lewis I; Korner H; McColl SR
    J Immunol; 2009 Mar; 182(5):3121-30. PubMed ID: 19234209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lessons from multiple sclerosis: models, concepts, observations.
    Wekerle H
    Ann Rheum Dis; 2008 Dec; 67 Suppl 3():iii56-60. PubMed ID: 19022815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemokines and chemokine receptors as therapeutic targets in lupus nephritis.
    Vielhauer V; Anders HJ; Schlöndorff D
    Semin Nephrol; 2007 Jan; 27(1):81-97. PubMed ID: 17336691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CCR6 regulates EAE pathogenesis by controlling regulatory CD4+ T-cell recruitment to target tissues.
    Villares R; Cadenas V; Lozano M; Almonacid L; Zaballos A; Martínez-A C; Varona R
    Eur J Immunol; 2009 Jun; 39(6):1671-81. PubMed ID: 19499521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.